Catalyst Wire Dossier Catalyst Wire Dossier
EMA withdrawal · 2023-05-04

EMA Withdrawn: NeuroBloc (botulinum toxin type B) — Sloan Pharma S.a.r.l

View source ↗

Summary

EMA withdrew NeuroBloc (botulinum toxin type B) from the market for the treatment of torticollis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NeuroBloc (botulinum toxin type B)

Snippet

Status: Withdrawn. Therapeutic area: Torticollis. MAH: Sloan Pharma S.a.r.l. Decision date: 04/03/2021